EXCELSIOR (4104) reported revenue of NT$1.02 billion for Oct 2026, +38.6% year on year and +6.4% from the previous month. Revenue for Jan–Oct 2026 was NT$8.5 billion (+17.2% year on year).
Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$960.2 million). →
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 5 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$1.02 billion | +38.6% | +6.4% |
| Sep 2026 | NT$960.2 million | +24.5% | +1.7% |
| Aug 2026 | NT$944.3 million | +32.2% | +12.0% |
| Jul 2026 | NT$843.5 million | +18.3% | -5.6% |
| Jun 2026 | NT$893.6 million | +16.1% | +27.4% |
| May 2026 | NT$701.7 million | -0.8% | -11.3% |
| Apr 2026 | NT$790.6 million | +14.7% | -6.1% |
| Mar 2026 | NT$841.6 million | +15.1% | +20.9% |
| Feb 2026 | NT$696 million | -3.4% | -13.6% |
| Jan 2026 | NT$805.3 million | +15.8% | +4.0% |
| Dec 2025 | NT$774.3 million | +0.6% | +1.2% |
| Nov 2025 | NT$764.9 million | +2.6% | +3.8% |
| Oct 2025 | NT$737.1 million | -3.4% | -4.4% |
| Sep 2025 | NT$771.1 million | +4.0% | +8.0% |
| Aug 2025 | NT$714.1 million | +6.7% | +0.1% |
| Jul 2025 | NT$713.1 million | +9.9% | -7.4% |
| Jun 2025 | NT$769.9 million | +6.1% | +8.9% |
| May 2025 | NT$707 million | -4.1% | +2.5% |
| Apr 2025 | NT$689.5 million | -1.0% | -5.7% |
| Mar 2025 | NT$731.5 million | +4.6% | +1.5% |
| Feb 2025 | NT$720.7 million | +25.3% | +3.6% |
| Jan 2025 | NT$695.6 million | -9.4% | -9.6% |
| Dec 2024 | NT$769.7 million | +5.9% | +3.3% |
| Nov 2024 | NT$745.4 million | -4.1% | -2.3% |
| Oct 2024 | NT$762.8 million | +12.2% | +2.9% |
Jan–Oct 2026 cumulative: NT$8.5 billion (+17.2% YoY)
Other Biotech & Medical companies
Compare with peers: EXCELSIOR vs PEC / EXCELSIOR vs Lotus Pharm / EXCELSIOR vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
| GKB | NT$748.3 million | -30.8% |
Company remark (original Chinese)
一一五年六月因佳醫創照健康股份有限公司及其子公司成為合併個體,使本月營收增加85,446仟元及本年累計營收增加389,450仟元。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16